CardioGenics (OTCMKTS:CGNH) vs. CURRENC Group (NASDAQ:CURR) Critical Comparison

CURRENC Group (NASDAQ:CURR) and CardioGenics (OTCMKTS:CGNH) are both services companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares CURRENC Group and CardioGenics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CURRENC Group	$43.39 million	0.56	N/A	N/A	N/A
CardioGenics	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CURRENC Group and CardioGenics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CURRENC Group	0	0	1	1	3.50
CardioGenics	0	0	0	0	0.00

CURRENC Group currently has a consensus target price of $3.50, indicating a potential upside of 573.08%. Given CURRENC Group’s stronger consensus rating and higher probable upside, equities research analysts plainly believe CURRENC Group is more favorable than CardioGenics.

Profitability

This table compares CURRENC Group and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CURRENC Group	N/A	N/A	N/A
CardioGenics	N/A	N/A	N/A

Insider & Institutional Ownership

56.0% of CURRENC Group shares are held by institutional investors. 17.8% of CURRENC Group shares are held by company insiders. Comparatively, 41.4% of CardioGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

CURRENC Group has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, CardioGenics has a beta of 3.13, suggesting that its share price is 213% more volatile than the S&P 500.

Summary

CURRENC Group beats CardioGenics on 6 of the 8 factors compared between the two stocks.

About CURRENC Group

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.